Abstract
With increasing level 1 evidence demonstrating improved detection of clinically significant prostate cancer and decreased detection of insignificant disease using multiparametric magnetic resonance imaging (mpMRI) in biopsy-naive men, the EAU decided to incorporate mpMRI into their prostate cancer guidelines in 2019. In consequence, a steady increase in use of mpMRI scans can be expected over the next few years which represents a major challenge for radiologists and healthcare systems.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
